UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, Provides FY20 EPS Outlook
Go back to UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, Provides FY20 EPS Outlook| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 20.16 +1.45 (7.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.71 | 52 Week High | $0.19 | |||
| Open | $18.96 | 52 Week Low | $0.07 | |||
| Day High | $21.18 | P/E | N/A | |||
| Day Low | $18.78 | EPS | $-0.01 | |||
| Volume | 5,245,143 | |||||
